Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Last Hour:
Last 24 Hours:

Hepatitis B Therapeutics Industry 2016 Global Market Growth, Trends, Demand, Share, Analysis to 2020

Thursday, October 13, 2016 1:10
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Hepatitis B is an infectious liver disease caused by the Hepatitis B Virus (HBV) and characterized by acute or chronic inflammation of the liver. Despite its status as a vaccine-preventable disease, it remains a serious global health concern. Incidence tends to be higher in countries with a significant number of migrants from medium and high-prevalence countries.

Browse more detail information about Hepatitis B Therapeutics in Major Developed Markets:

Approximately 350 million people worldwide are infected with chronic hepatitis B, which causes significant morbidity and mortality. Around 780,000 patients die from hepatitis B each year, of which 650,000 deaths are due to complications such as cirrhosis and liver cancer. Despite this, diagnosis and treatment rates are poor, stemming from its asymptomatic nature.

Get a PDF Sample of Hepatitis B Therapeutics in Major Developed Markets:

Scope of Hepatitis B Therapeutics in Major Developed Markets:

The current hepatitis B market contains mainly nucleoside analog reverse transcriptase inhibitors, nucleotide analogs, and interferons.

- Will these drugs continue to dominate hepatitis B treatment?

With 81 active pipeline molecules, most of the investigational drug candidates are small molecules and vaccines, comprising 64% of the pipeline.

- What are the most prominent small molecules and vaccines in the pipeline?

- Do the pipeline molecules offer advantages over commercially proven mechanisms?

Analysis of clinical trials since 2006 has identified a high rate of attrition in hepatitis B products.

- How do failure rates vary by product stage of development, molecule type, and mechanism of action?

- How do other factors such as average trial duration and trial size influence the costs and risks associated with product development?

Over the 2014–2021 forecast period, the hepatitis B market in the eight major markets is expected to increase in value at a CAGR of 2.3% from $2.9 billion to $3.5 billion.

- Which markets make the most significant contribution to the current market size?

- What are the epidemiology trends in these markets?

- Which factors will influence growth rates in the different major markets?

Despite generic sales erosion resulting from patent expirations, the uptake of premium therapies tenofovir and entecavir will contribute to significant market growth over the forecast period.

- Will patent expirations or emerging pipeline molecules threaten the commercial success of existing drugs?

- Which patent expirations will have the most significant impact on the market?


Reasons to buy Hepatitis B Therapeutics in Major Developed Markets:

This report will enable you to –

- Understand the clinical context of hepatitis B by considering symptoms, etiology, pathophysiology, epidemiology, diagnosis, and treatment options.

- Identify the therapeutic strategies, products, and companies that dominate the current marketed products landscape and recognize gaps and areas of unmet need.

- Appreciate key pipeline trends by molecule type, route of administration, mechanism of action, and novelty.

- Consider market opportunities and potential risks by looking at trends in clinical trial size, duration, and failure rate by stage of development, molecule type, and mechanism of action.

- Recognize the late-stage pipeline molecules that have demonstrated strong therapeutic potential by examining clinical trial data and multi-scenario product forecast projections.

- Compare treatment usage patterns, annual therapy costs, and market growth projections for the US, Canada, the UK, France, Germany, Italy, Spain, and Japan.

- Discover trends in licensing and co-development deals concerning hepatitis B products and identify the major strategic consolidations that have shaped the commercial landscape.


Have any query? ask our expert @


List of Figures, Tables and Charts Available in Hepatitis B Therapeutics in Major Developed Markets to 2021 – Increasing Number of Migrants from High-Prevalence Regions to Drive Market Growth

1.1 List of Tables

Table 1: Chronic Hepatitis B Prevalence in Countries that are Main Sources of Migration to US 9

Table 2: Comparison of Drugs that Treat Hepatitis B 15

Table 3: Immigration from High-Prevalence Regions to US, 2010 and 2013 46

Table 4: Hepatitis B Therapeutics Market, Global, Pipeline Products, Discovery, 2015 55

Table 5: Hepatitis B Therapeutics Market, Global, Pipeline Products, Preclinical, 2015 56

Table 6: Hepatitis B Therapeutics Market, Global, Pipeline Products, Phase I, 2015 57

Table 7: Hepatitis B Therapeutics Market, Global, Pipeline Products, Phase II, 2015 58

Table 8: Hepatitis B Therapeutics Market, Global, Pipeline Products, Phase III, 2015 58

Table 9: Hepatitis B Therapeutics Market, Global, Market Forecast, 2014-2021 59

Table 10: Hepatitis B Therapeutics Market, US, Market Forecast, 2014-2021 59

Table 11: Hepatitis B Therapeutics Market, Canada, Market Forecast, 2014-2021 60

Table 12: Hepatitis B Therapeutics Market, UK, Market Forecast, 2014-2021 60


Get Discount on Hepatitis B Therapeutics in Major Developed Markets:


About Absolute Report:
Absolute Reports is an upscale platform to help key personnel in the business world in strategizing and taking visionary decisions based on facts and figures derived from in-depth market research. We are one of the top report resellers in the market dedicated towards bringing you an ingenious concoction of data parameters.

Mr. Ameya Pingaley

Absolute Reports
+1-408 520 9750
Get more market research related news @

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Total 1 comment
  • Am so happy, i never believe i will be this happy again in life, I was working as an air-hoster ( cabby crew ) for 5 years but last year i loose my job because of this deadly disease called Hepatitis B (HbsAg), I never felt sick or have any symptom, till all workers were ask to bring their doctor report, that was how i got tested and i found out that am HbsAg positive that make me loose my job, because it was consider as an STD and is incurable disease, i was so depress was thinking of committing suicide, till i explain to a friend of mine, who always said to me a problem share is a problem solved, that was how she directed me to this clinic called HEALTH MED LAB CLINIC, that was how i contacted them and i get medication from them and i got cured for real, I just went back to my work and they also carry out the test to be real sure and i was negative. Please contact this clinic if you are hepatitis B positive their email is ( ) they are life saver.

Top Stories
Recent Stories



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.